LOAN AGREEMENT Dated as of March 7, 2022 among UROGEN PHARMA, INC. (as Borrower, and a Credit Party), UROGEN PHARMA LTD. (as Parent, and a Credit Party), THE OTHER GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional...Loan Agreement • May 10th, 2022 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT (this “Agreement”), dated as of March 7, 2022 (the “Effective Date”) by and among UROGEN PHARMA, INC., a Delaware corporation (as “Borrower” and a Credit Party), UROGEN PHARMA LTD., a company incorporated in Israel with company registration number 513537621 (as “Parent” and a Credit Party), the other Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extens
Manufacturing & Supply Agreement Between:Supply Agreement • May 10th, 2022 • UroGen Pharma Ltd. • Pharmaceutical preparations
This Manufacturing & Supply Agreement (hereinafter referred to as the “Agreement”) is made on April 24, 2020 (hereinafter referred to as the “Effective Date”) by and between:
